A naturally occurring E-series prostaglandin produced by the COX metabolism of ω-3 arachidonic acid. It was first isolated and characterized as a product of ram seminal vesicle microsomes. The relative abundance of Δ17-PGE1 in humans and other animals is low in comparison with PGE2, and is likely to be a reflection of precursor fatty acid abundance in the phospholipid PUFA reservoir. Definitive studies on the biosynthesis of Δ17-PGE1 in intact animals have not been done. Δ17-PGE1 is about half as potent as PGE1 as an inhibitor of ADP-induced aggregation of rabbit PRP. In human PRP, Δ17-PGE1 is a more potent antiplatelet agonist than PGE1, with an IC50 of about 30 nM.3 The vascular effects of Δ17-PGE1 have not been reported.
1. Samel, N., et al. 1987. Prostaglandins. 33: 137-146. PMID: 3473571
2. Kobzar, G., et al. 1993. Comp Biochem Physiol C. 106: 489-494. PMID: 7904921
3. Kobzar, G., et al. 1991. Comp Biochem Physiol C. 40: 179-180. PMID: 7904921
산타크루즈바이오테크놀러지는 생물의학연구에 필요한 제품을 개발하는 선구자입니다. Toll Free 1-800-457-3801로 연락주세요. Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. 판권소유. "Santa Cruz Biotechnology", 와 Santa Cruz Biotechnology, Inc. 로고, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", 및 San Juan Ranch 로고, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz"와 "EZ Touch" 는 Santa Cruz Biotechnology, Inc의 등록된 상표입니다. 모든 상표는 각자 소유주의 소유입니다.